AU2014352404B2 - Dihydropyrimidine compounds and their application in pharmaceuticals - Google Patents
Dihydropyrimidine compounds and their application in pharmaceuticals Download PDFInfo
- Publication number
- AU2014352404B2 AU2014352404B2 AU2014352404A AU2014352404A AU2014352404B2 AU 2014352404 B2 AU2014352404 B2 AU 2014352404B2 AU 2014352404 A AU2014352404 A AU 2014352404A AU 2014352404 A AU2014352404 A AU 2014352404A AU 2014352404 B2 AU2014352404 B2 AU 2014352404B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- mmol
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CC(N=C(*)NC1*)=C1C(**)=O Chemical compound *CC(N=C(*)NC1*)=C1C(**)=O 0.000 description 9
- XPALEVKXWXIQRM-QELUHHJYSA-N C/C(/Cl)=C(/[C@@H]1N=C(c2ncc[s]2)NC(CN(C2)[C@H](CCC(O)=O)CCC2(F)F)=C1C(OC)=O)\C=C Chemical compound C/C(/Cl)=C(/[C@@H]1N=C(c2ncc[s]2)NC(CN(C2)[C@H](CCC(O)=O)CCC2(F)F)=C1C(OC)=O)\C=C XPALEVKXWXIQRM-QELUHHJYSA-N 0.000 description 1
- CCPVCZYOGHGBBD-OWLJTODASA-N CC(C[C@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CC1(F)F)C(O)=O Chemical compound CC(C[C@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(ccc(F)c3)c3Cl)=C2C(OC)=O)CC1(F)F)C(O)=O CCPVCZYOGHGBBD-OWLJTODASA-N 0.000 description 1
- VZETVCNDZVNTNA-HNHGDDPOSA-N CC1(C[I-][C@H](CCCCC(O)=O)C1)F Chemical compound CC1(C[I-][C@H](CCCCC(O)=O)C1)F VZETVCNDZVNTNA-HNHGDDPOSA-N 0.000 description 1
- JIQRTJRFRXOOQE-AWEZNQCLSA-N CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(C)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O JIQRTJRFRXOOQE-AWEZNQCLSA-N 0.000 description 1
- GSBYZFBWWGLUDE-AJTFCVKESA-N CCOC(C1=C(CN(C2)C(CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)C(CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O GSBYZFBWWGLUDE-AJTFCVKESA-N 0.000 description 1
- UNIBPYFUCIOXPF-JQHMPQBSSA-N CCOC(C1=C(CN(C2)[C@@H](CC(C)C(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CC(C)C(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O UNIBPYFUCIOXPF-JQHMPQBSSA-N 0.000 description 1
- WWDXQSYEYUUOKN-UNMCSNQZSA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)C(C)(C)C2(F)F)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)C(C)(C)C2(F)F)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O WWDXQSYEYUUOKN-UNMCSNQZSA-N 0.000 description 1
- DBDKBBQRJYNELV-KKSFZXQISA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O DBDKBBQRJYNELV-KKSFZXQISA-N 0.000 description 1
- NHFHJCVFAUXWIZ-KKSFZXQISA-N CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CCC(C)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O NHFHJCVFAUXWIZ-KKSFZXQISA-N 0.000 description 1
- SGICWDVAQGILPX-DSSKRPNASA-N CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1/C(/C=C)=C(/C)\Cl)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)C(C)(C)C2F)NC(c2ncc[s]2)=N[C@H]1/C(/C=C)=C(/C)\Cl)=O SGICWDVAQGILPX-DSSKRPNASA-N 0.000 description 1
- UXFXZBOCQKBHLS-VLIAUNLRSA-N CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O UXFXZBOCQKBHLS-VLIAUNLRSA-N 0.000 description 1
- YBARZJQSVMWKFZ-ZHRRBRCNSA-N CCOC(C1=C(CN(C2)[C@H](CCCCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@H](CCCCC(O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O YBARZJQSVMWKFZ-ZHRRBRCNSA-N 0.000 description 1
- IFHIMFZONAFTPT-CXBCTULXSA-N CCOC(C1=C(CN(CC(C2)(F)F)[C@@H]2C(C)CC(O)=O)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN(CC(C2)(F)F)[C@@H]2C(C)CC(O)=O)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O IFHIMFZONAFTPT-CXBCTULXSA-N 0.000 description 1
- PKOJDTKJNZKPGE-UHFFFAOYSA-N CCOC(C1=C(CN)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O PKOJDTKJNZKPGE-UHFFFAOYSA-N 0.000 description 1
- HVMPCEHHUXAGFT-XNLYHCEPSA-N CC[IH][F]C1(C(C)(C)[C@H](CCC(C)=O)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3Cl)=C2C(OC)=O)C1)F Chemical compound CC[IH][F]C1(C(C)(C)[C@H](CCC(C)=O)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3Cl)=C2C(OC)=O)C1)F HVMPCEHHUXAGFT-XNLYHCEPSA-N 0.000 description 1
- ZQPVXXUOCLWIJM-YFKPBYRVSA-N OC(CC[C@@H](C1)NCC1(F)F)=O Chemical compound OC(CC[C@@H](C1)NCC1(F)F)=O ZQPVXXUOCLWIJM-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310590683.6 | 2013-11-19 | ||
| CN201310590683 | 2013-11-19 | ||
| CN201410108925.8 | 2014-03-23 | ||
| CN201410108925 | 2014-03-23 | ||
| PCT/CN2014/091444 WO2015074546A1 (en) | 2013-11-19 | 2014-11-18 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014352404A1 AU2014352404A1 (en) | 2016-02-18 |
| AU2014352404B2 true AU2014352404B2 (en) | 2018-07-19 |
Family
ID=53178948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014352404A Active AU2014352404B2 (en) | 2013-11-19 | 2014-11-18 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9498479B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3071564B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6524081B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160077050A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104650068B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014352404B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2920415A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016006564A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2678990C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015074546A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2927373C (en) | 2013-11-27 | 2021-07-13 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| SG11201605896WA (en) | 2014-03-28 | 2016-08-30 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals |
| WO2016124126A1 (en) | 2015-02-07 | 2016-08-11 | Sunshine Lake Pharma Co., Ltd. | Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals |
| US20160286398A1 (en) * | 2015-03-23 | 2016-09-29 | Qualcomm Incorporated | Schedule selection and connection setup between devices participating in a nan data link |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN108135979A (zh) | 2015-11-03 | 2018-06-08 | 豪夫迈·罗氏有限公司 | Hbv衣壳组装抑制剂和干扰素的组合疗法 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10472345B2 (en) | 2016-02-04 | 2019-11-12 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
| EP3426245B1 (en) | 2016-03-07 | 2022-12-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| EP3468561A4 (en) | 2016-06-10 | 2019-12-04 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| EP3503894A1 (en) | 2016-08-24 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue |
| CA3037218A1 (en) * | 2016-11-18 | 2018-05-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| WO2019001396A1 (en) * | 2017-06-26 | 2019-01-03 | Sunshine Lake Pharma Co., Ltd. | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE |
| AU2018291688B2 (en) | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| UY37861A (es) | 2017-08-28 | 2019-03-29 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| CA3079557A1 (en) * | 2017-10-18 | 2019-04-25 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| KR102819704B1 (ko) | 2018-11-21 | 2025-06-11 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN113831359A (zh) * | 2020-06-24 | 2021-12-24 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN118955353A (zh) * | 2024-10-14 | 2024-11-15 | 南京恒远科技开发有限公司 | 一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2008154818A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution fluorophényle |
| CN101328169B (zh) | 2007-06-18 | 2011-05-25 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| PT2159224E (pt) | 2007-06-18 | 2012-10-24 | Sunshine Lake Pharma Co Ltd | Tiazolil dihidropirimidinas substituídas com bromo-fenilo |
| CN101328168B (zh) * | 2007-06-18 | 2011-09-07 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| CN104302626B (zh) | 2012-01-06 | 2016-09-07 | 爱尔兰詹森科学公司 | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 |
| WO2013144129A1 (en) * | 2012-03-31 | 2013-10-03 | F. Hoffmann-La Roche Ag | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| JP6263533B2 (ja) | 2012-08-24 | 2018-01-17 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | ジヒドロピリミジン化合物及び医薬におけるその適用 |
| CN103664897B (zh) * | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) * | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN103664899B (zh) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| US20150292045A1 (en) | 2012-11-09 | 2015-10-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| WO2014153459A2 (en) | 2013-03-20 | 2014-09-25 | Indiana University Research And Technology Corporation | Fluorescent-hap: a diagnostic stain for hbv cores in cells |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| CA2927373C (en) * | 2013-11-27 | 2021-07-13 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
-
2014
- 2014-11-18 CA CA2920415A patent/CA2920415A1/en not_active Abandoned
- 2014-11-18 EP EP14863769.7A patent/EP3071564B1/en active Active
- 2014-11-18 JP JP2016530248A patent/JP6524081B2/ja active Active
- 2014-11-18 WO PCT/CN2014/091444 patent/WO2015074546A1/en not_active Ceased
- 2014-11-18 CN CN201410657898.XA patent/CN104650068B/zh active Active
- 2014-11-18 MX MX2016006564A patent/MX2016006564A/es unknown
- 2014-11-18 AU AU2014352404A patent/AU2014352404B2/en active Active
- 2014-11-18 KR KR1020167008618A patent/KR20160077050A/ko not_active Withdrawn
- 2014-11-18 US US15/022,562 patent/US9498479B2/en active Active
- 2014-11-18 RU RU2016122908A patent/RU2678990C1/ru active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104650068A (zh) | 2015-05-27 |
| RU2016122908A (ru) | 2017-12-25 |
| EP3071564A4 (en) | 2017-04-26 |
| WO2015074546A1 (en) | 2015-05-28 |
| MX2016006564A (es) | 2017-09-12 |
| JP2016537358A (ja) | 2016-12-01 |
| US9498479B2 (en) | 2016-11-22 |
| AU2014352404A1 (en) | 2016-02-18 |
| HK1224286A1 (en) | 2017-08-18 |
| CA2920415A1 (en) | 2015-05-28 |
| KR20160077050A (ko) | 2016-07-01 |
| US20160206616A1 (en) | 2016-07-21 |
| JP6524081B2 (ja) | 2019-06-05 |
| EP3071564B1 (en) | 2020-08-05 |
| CN104650068B (zh) | 2018-08-10 |
| EP3071564A1 (en) | 2016-09-28 |
| RU2678990C1 (ru) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014352404B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| EP3122747B1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| US9340538B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| KR102667040B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY Free format text: FORMER OWNER(S): SUNSHINE LAKE PHARMA CO., LTD. |
|
| PC | Assignment registered |
Owner name: SUNSHINE LAKE PHARMA CO., LTD. Free format text: FORMER OWNER(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED |